Direct award for the acquisition of AMINOCAPROIC ACID [25%; VIALS/AMPOULES; IV] and AMINOCAPROIC ACID [3G; SACHET]

This tender announces a direct award procedure for the acquisition of two specific pharmaceutical products: Aminocaproic Acid in a 25% concentration, supplied in vials or ampoules for intravenous (IV) administration, and Aminocaproic Acid in a 3g dosage, provided in sachets. Aminocaproic Acid is an antifibrinolytic medication used to prevent or treat excessive bleeding by inhibiting the breakdown of blood clots. The intravenous formulation is typically used in more critical situations, while the sachet form might be for oral administration or specific dosage requirements. This direct award suggests a specific need or urgency, or potentially a framework agreement is already in place. The procuring entity requires a reliable supply of these essential medications for patient treatment. Bidders are expected to meet stringent pharmaceutical quality standards. The tender focuses on securing these specific formulations and dosages to ensure appropriate medical interventions are available. This procurement is crucial for managing bleeding disorders and supporting critical care services within the healthcare system.

This is a supplies contract in the health and medical services, trade and industry and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 1,373.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.